Edwards Lifesciences Co. (NYSE:EW – Get Free Report) VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 11th. The stock was sold at an average price of $66.77, for a total transaction of $333,850.00. Following the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at approximately $3,133,916.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Edwards Lifesciences Trading Up 1.7 %
NYSE EW opened at $68.25 on Thursday. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The stock has a 50-day simple moving average of $73.32 and a 200 day simple moving average of $83.72. The company has a current ratio of 3.71, a quick ratio of 2.87 and a debt-to-equity ratio of 0.08. The company has a market capitalization of $41.11 billion, a PE ratio of 29.42, a P/E/G ratio of 2.79 and a beta of 1.13.
Edwards Lifesciences (NYSE:EW – Get Free Report) last announced its quarterly earnings results on Wednesday, July 24th. The medical research company reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The company had revenue of $1.63 billion during the quarter, compared to analysts’ expectations of $1.65 billion. During the same period in the prior year, the business posted $0.66 EPS. Edwards Lifesciences’s revenue was up 6.7% on a year-over-year basis. Research analysts forecast that Edwards Lifesciences Co. will post 2.7 EPS for the current year.
Institutional Investors Weigh In On Edwards Lifesciences
Wall Street Analysts Forecast Growth
A number of equities research analysts recently weighed in on the company. StockNews.com cut Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Thursday, July 25th. Daiwa America upgraded Edwards Lifesciences to a “strong-buy” rating in a research note on Wednesday, July 31st. Royal Bank of Canada cut their price target on Edwards Lifesciences from $101.00 to $85.00 and set an “outperform” rating for the company in a report on Thursday, July 25th. Baird R W lowered shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 25th. Finally, Truist Financial cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and lowered their price objective for the company from $110.00 to $82.00 in a research report on Thursday, July 25th. Fifteen analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $80.81.
View Our Latest Report on Edwards Lifesciences
Edwards Lifesciences Company Profile
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.
Read More
- Five stocks we like better than Edwards Lifesciences
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Alnylam Stock Soars 65%: Find Out What’s Behind the Gains
- Upcoming IPO Stock Lockup Period, Explained
- Goldilocks CPI Report Leads Market to Sell Off, Lower Lows Ahead
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- GameStop: Earnings Won’t Save It, Dilution Points to Trouble
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.